FSA
AIMT

Franklin Street Advisors’s Aimmune Therapeutics AIMT Stock Holding History

Franklin Street Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-16,880
Closed -$454K – 168
2018
Q2 		$454K Buy
16,880
+460
+3% +$14.1K 0.07% 106
2018
Q1 		$523K Hold
16,420
– – 0.08% 94
2017
Q4 		$621K Buy
16,420
+5,000
+44% +$161K 0.09% 99
2017
Q3 		$283K Buy
11,420
+720
+7% +$15.5K 0.05% 123
2017
Q2 		$220K Sell
10,700
-10,000
-48% -$191K 0.04% 130
2017
Q1 		$450K Buy
+20,700
New +$425K 0.08% 109

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Franklin Street Advisors's AIMT Position: Q3 2018 in Review

Franklin Street Advisors sold out of Aimmune Therapeutics (AIMT) in Q3 2018, closing a stake of 16,880 shares — an estimated $454K sold.

Franklin Street Advisors first reported a position in AIMT in Q1 2017 and held it in 6 quarters. The position peaked at $621K in Q4 2017. 142 funds tracked by Wall St. Rank hold AIMT as of Q3 2018.

  • Franklin Street Advisors reported no remaining Aimmune Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Franklin Street Advisors sold 16,880 Aimmune Therapeutics shares in Q3 2018, an estimated $454K.
  • Franklin Street Advisors first reported a position in Aimmune Therapeutics in Q1 2017 and held it in 6 quarters.
  • Franklin Street Advisors's Aimmune Therapeutics position peaked at $621K in Q4 2017.
  • 142 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2018.

Based on Franklin Street Advisors's 13F filing for Q3 2018, filed 5 Oct 2018.